2023
FRI694 Hypercalcemia And Renal Failure As Initial Presentation Of A Rare Case Of Primary Splenic Large B Cell Lymphoma
Ding N, Majumdar S. FRI694 Hypercalcemia And Renal Failure As Initial Presentation Of A Rare Case Of Primary Splenic Large B Cell Lymphoma. Journal Of The Endocrine Society 2023, 7: bvad114.462. PMCID: PMC10555323, DOI: 10.1210/jendso/bvad114.462.Peer-Reviewed Original ResearchSplenic large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaDihydroxy vitamin DRenal failureVitamin DPg/mLCell lymphomaPg/Diffuse large B-cell lymphomaR-CHOP therapyPatient underwent splenectomyBence Jones proteinuriaBone marrow biopsyPrimary splenic lymphomaNon-Hodgkin lymphomaPrimary care doctorsAbdominal painElderly patientsInitial presentationUnderwent splenectomyCalcium 1000Further workupMRI abdomenRare etiologyRationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event
Mentz R, Ward J, Hernandez A, Lepage S, Morrow D, Sarwat S, Sharma K, Solomon S, Starling R, Velazquez E, Williamson K, Zieroth S, Braunwald E. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. Journal Of Cardiac Failure 2023, 29: 922-930. PMID: 36796671, DOI: 10.1016/j.cardfail.2023.02.001.Peer-Reviewed Original ResearchConceptsSac/ValSacubitril/valsartanHeart failure eventsPARAGON-HF trialWHF eventNT-proBNPEjection fractionHeart failureClinical outcomesAmino-terminal pro-B-type natriuretic peptide levelsTerminal pro-B-type natriuretic peptide levelsB-type natriuretic peptide levelsDe novo HFChronic heart failureNatriuretic peptide levelsPrimary efficacy endpointPg/mLEfficacy endpointSafety endpointSecondary endpointsSymptomatic hypotensionBaseline characteristicsRenal functionStable patientsBlack patientsHospitalisations for heart failure: increased palliative care referrals − a veterans affairs hospital initiative
Gruen J, Gandhi P, Gillespie-Heyman S, Shamas T, Adelman S, Ruskin A, Bauer M, Merchant N. Hospitalisations for heart failure: increased palliative care referrals − a veterans affairs hospital initiative. BMJ Supportive & Palliative Care 2023, 14: e1309-e1316. PMID: 36609533, DOI: 10.1136/spcare-2022-004118.Peer-Reviewed Original ResearchHeart failurePalliative careHF admissionsMedian B-type natriuretic peptideB-type natriuretic peptidePalliative care referralCare educationVeterans Affairs hospitalPercentage of referralsStudy-Act cyclesQuality of lifeMultiple PDSA cyclesPg/mLPC consultHF managementHF patientsBaseline medianCare referralHospital InitiativeReferral guidelinesSignificant morbidityNatriuretic peptideMean ageNew referralsReferral criteriaNasal host response-based screening for undiagnosed respiratory viruses: a pathogen surveillance and detection study
Cheemarla N, Hanron A, Fauver J, Bishai J, Watkins T, Brito A, Zhao D, Alpert T, Vogels C, Ko A, Schulz W, Landry M, Grubaugh N, van Dijk D, Foxman E. Nasal host response-based screening for undiagnosed respiratory viruses: a pathogen surveillance and detection study. The Lancet Microbe 2023, 4: e38-e46. PMID: 36586415, PMCID: PMC9835789, DOI: 10.1016/s2666-5247(22)00296-8.Peer-Reviewed Original ResearchConceptsRespiratory virus panelPg/mLCXCL10 concentrationsSARS-CoV-2Bacterial pathobiontsRespiratory virusesSARS-CoV-2 negative samplesViral respiratory infectionsSARS-CoV-2 positive samplesClinical virology laboratoryHealth care systemVirus-positive samplesQuantitative RT-PCRInfluenza C virusSymptomatic patientsRespiratory infectionsSeasonal coronavirusesNasopharyngeal swabsVirus panelC virusCommon virusesCXCL10Host responseInterferon responseVirology laboratory
2021
The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial
Ezekowitz JA, Alemayehu W, Rathwell S, Grant AD, Fiuzat M, Whellan DJ, Ahmad T, Adams K, Piña IL, Cooper LS, Januzzi JL, Leifer ES, Mark D, O'Connor CM, Felker GM. The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial. ESC Heart Failure 2021, 9: 77-86. PMID: 34784657, PMCID: PMC8787989, DOI: 10.1002/ehf2.13692.Peer-Reviewed Original ResearchConceptsBody mass indexLower body mass indexNT-proBNPAtrial fibrillationN-terminal pro B-type natriuretic peptide valuesMedian body mass indexHigher Body Mass IndexGUIDE-IT trialNT-proBNP targetWorse renal functionNT-proBNP levelsReduced ejection fractionCent of patientsNatriuretic peptide valuesGlomerular filtration rateHeart failure therapyInfluence of comorbiditiesSeverity of illnessEvidence-based therapiesPg/mLCare armLower eGFRRenal dysfunctionUsual careRenal functionActive B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan
Dillon EM, Wei SD, Gupta DK, Nian H, Rodibaugh BS, Bachmann KN, Naftilan AJ, Stevenson LW, Brown NJ. Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan. Journal Of Cardiac Failure 2021, 27: 1231-1239. PMID: 34133968, PMCID: PMC8578199, DOI: 10.1016/j.cardfail.2021.05.026.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanSacubitril/valsartan treatmentHeart failureBNP1-32NT-proBNPValsartan treatmentActive B-type natriuretic peptideEnd-stage renal diseaseB-type natriuretic peptideNT-proBNP immunoassaysPg/mLRenal diseaseNatriuretic peptideBNP productionHealthy volunteersBNPPg/ValsartanPatientsInhibition of degradationPeptide immunoassayBNP degradationTreatmentImmunoassayMS accountsDifferences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction
Daubert MA, Yow E, Barnhart HX, Piña IL, Ahmad T, Leifer E, Cooper L, Desvigne‐Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, O’Connor C, Felker GM. Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal Of The American Heart Association 2021, 10: e019712. PMID: 33955231, PMCID: PMC8200692, DOI: 10.1161/jaha.120.019712.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiomarkersCanadaCause of DeathFemaleFollow-Up StudiesGuideline AdherenceHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisProtein PrecursorsRetrospective StudiesSex DistributionSex FactorsStroke VolumeUnited StatesConceptsReduced ejection fractionNT-proBNP responseGuideline-directed medical therapyGUIDE-IT trialHeart failureEjection fractionNT-proBNPPrognostic valuePg/mLHF hospitalizationMedical therapyEquivalent prognostic valueNT-proBNP reductionNT-proBNP valuesGreater prognostic valueNonischemic causesClinical characteristicsClinical outcomesImproved outcomesLandmark analysisPrognostic biomarkerTherapeutic goalsConclusions MenSecondary analysisWomen
2020
Relationship between NT-pro Brain Natriuretic Peptide and Filling Pressures in Ambulatory Patients with Left Ventricular Assist Devices and Accuracy to Detect Need for Optimization
Abbas A, Akintoye E, Duque E, Briasoulis A, Alvarez P. Relationship between NT-pro Brain Natriuretic Peptide and Filling Pressures in Ambulatory Patients with Left Ventricular Assist Devices and Accuracy to Detect Need for Optimization. The Journal Of Heart And Lung Transplantation 2020, 39: s344. DOI: 10.1016/j.healun.2020.01.390.Peer-Reviewed Original ResearchPulmonary capillary wedge pressureRight atrial pressureVentricular assist devicePulmonary artery pressureNT-proBNPAmbulatory patientsAssist deviceNatriuretic peptideN-terminal pro-brain natriuretic peptideNT-pro-brain natriuretic peptidePro-brain natriuretic peptideCapillary wedge pressureNT-proBNP levelsRight heart catheterizationMedian NT-proBNPBrain natriuretic peptideBest cutoff valuePg/mLWedge pressureArtery pressureHeart catheterizationAtrial pressurePatient characteristicsHemodynamic optimizationNoninvasive marker
2019
Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial
Kosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.Peer-Reviewed Original ResearchPlacebo-controlled trialReduced ejection fractionEffect of dapagliflozinHeart failureFunctional statusSGLT-2iEjection fractionML/min/m2Double-blind placebo-controlled trialCo-primary end pointsDisease-specific health statusHigh-risk patient populationLarge cardiovascular outcome trialsManifest heart failureUrgent HF visitsKey secondary endpointCardiovascular outcome trialsMajority of patientsMin/m2Type 2 diabetesPg/mLExploratory endpointsHF visitsHFrEF patientsSGLT2i dapagliflozinEarlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature
Liu C, Zhao Z, Wang O, Li M, Xing X, Hsieh E, Fukumoto S, Jiang Y, Xia W. Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature. Calcified Tissue International 2019, 105: 476-486. PMID: 31486862, DOI: 10.1007/s00223-019-00597-y.Peer-Reviewed Original ResearchConceptsAutosomal dominant hypophosphatemic ricketsLower extremity deformitiesDominant hypophosphatemic ricketsExtremity deformitiesOnset ageHypophosphatemic ricketsFibroblast growth factor 23Growth factor 23Onset of diseaseRU/mLHistory of ricketsEarlier onset ageAge of onsetRare hereditary disorderPg/mLGenotype-phenotype correlationI-FGF23Symptomatic patientsFactor 23More patientsSerum phosphateClinical manifestationsLaboratory examinationsOvert symptomsMutation carriersSacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial
Velazquez E, Ambrosy A, Morrow D, McCague K, Duffy C, O'Brien T, Rocha R, DeVore A, Braunwald E. Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial. Journal Of Cardiac Failure 2019, 25: s80. DOI: 10.1016/j.cardfail.2019.07.227.Peer-Reviewed Original ResearchAcute decompensated HFPIONEER-HF trialHeart failureNT-proBNPBlack patientsPg/mLAngioedema eventsHospital initiationClinical outcomesAcute decompensated heart failureAngiotensin receptor neprilysin inhibitorPre-specified subgroup analysisPrior heart failureACEI/ARBDecompensated heart failureNatriuretic peptide levelsSacubitril/valsartanImproved clinical outcomesSelf-reported raceCV deathEnalapril armHemodynamic stabilizationSymptomatic hypotensionRenal functionNeprilysin inhibitorOR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials
Wolf M, Rubin J, Achebe M, Econs M, Peacock M, Imel E, Thomsen L, Carpenter T, Weber T, Zoller H. OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials. Journal Of The Endocrine Society 2019, 3: or13-3. PMCID: PMC6554827, DOI: 10.1210/js.2019-or13-3.Peer-Reviewed Original ResearchIron deficiency anemiaPg/mLFerric carboxymaltoseIron isomaltosideVitamin DIntact FGF23Day 1Day 35Bone turnoverPhosphate excretionIIM groupCorrection of IDADay 8Urinary fractional phosphate excretionBone-specific alkaline phosphataseFractional phosphate excretionNew intravenous iron preparationsIncidence of hypophosphatemiaSevere hypersensitivity reactionsGrowth factor 23Intravenous iron preparationsRenal phosphate excretionRandomized Controlled TrialsRenal phosphate wastingSpecific alkaline phosphatasePrimary Cortisol Deficiency and Growth Hormone Deficiency in a Neonate With Hypoglycemia: Coincidence or Consequence?
Gujral J, Yau M, Yang AC, Kastury R, Romero CJ, Wallach E, Wilkes M, Costin G, Rapaport R. Primary Cortisol Deficiency and Growth Hormone Deficiency in a Neonate With Hypoglycemia: Coincidence or Consequence? Journal Of The Endocrine Society 2019, 3: 838-846. PMID: 30963141, PMCID: PMC6447946, DOI: 10.1210/js.2018-00386.Peer-Reviewed Original ResearchGrowth hormone deficiencyGH deficiencyGH secretionGH levelsSerum cortisolHormone deficiencyIGF-1Receptor defectElevated transaminase levelsRandom GH levelsTransient GH deficiencyEpisodes of hypoglycemiaMelanocortin 2 receptor geneHours of lifeFull-term boyUndetectable serum cortisolPg/mLMolecular genetic testingGlucocorticoid replacementHydrocortisone replacementTransaminase levelsCortisol deficiencyGH therapyNeonatal hypoglycemiaACTH levels
2018
Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors
Strosberg D, Schneider EB, Onesti J, Saunders N, Konda B, Shah M, Dillhoff M, Schmidt CR, Shirley LA. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors. Annals Of Surgical Oncology 2018, 25: 3613-3620. PMID: 30182331, DOI: 10.1245/s10434-018-6741-x.Peer-Reviewed Original ResearchConceptsRepeat transarterial chemoembolizationMetastatic neuroendocrine tumorsTransarterial chemoembolizationPancreastatin levelsNeuroendocrine tumorsOverall survivalPrognostic impactImproved overall survivalProgressive liver diseaseFirst transarterial chemoembolizationWorse overall survivalUseful prognostic indicatorLong-term survivalPg/mLConclusionsFor patientsPost TACECarcinoid syndromeTACE treatmentLiver metastasesPatient demographicsImproved survivalLiver diseasePoor outcomePrognostic indicatorResultsA total
2017
One‐Hour Postoperative Parathyroid Hormone Levels Do Not Reliably Predict Hypocalcemia After Thyroidectomy
Sahli Z, Najafian A, Kahan S, Schneider E, Zeiger M, Mathur A. One‐Hour Postoperative Parathyroid Hormone Levels Do Not Reliably Predict Hypocalcemia After Thyroidectomy. World Journal Of Surgery 2017, 42: 2128-2133. PMID: 29290070, PMCID: PMC5991999, DOI: 10.1007/s00268-017-4444-2.Peer-Reviewed Original ResearchConceptsPostoperative parathyroid hormone levelsPg/mLParathyroid hormone levelsPostoperative PTHPTH levelsBiochemical hypocalcemiaTotal thyroidectomyCalcium supplementationProspective studyHormone levelsAppropriate calcium supplementationDefinitive study designPostoperative biochemical hypocalcemiaAdditional prospective studiesNormal PTH levelsPTH decreaseCompletion thyroidectomyConsecutive patientsSerum calciumLow PTHPTH 1HypocalcemiaIRB approvalThyroidectomyPTHSingle Dose Of Bisphosphonate To Treat Infantile Hypercalcemia
Patel N, Carpenter T, Genel M. Single Dose Of Bisphosphonate To Treat Infantile Hypercalcemia. AACE Clinical Case Reports 2017, 3: e246-e250. DOI: 10.4158/ep161536.cr.Peer-Reviewed Original ResearchSubcutaneous fat necrosisSingle doseSevere hypercalcemiaDihydroxyvitamin DParathyroid hormonePTH parathyroid hormoneLife-threatening complicationsTreatment of hypercalcemiaLow calcium dietWeeks of lifePosterior upper armPg/mLAggressive hydrationTerm neonatesCalcium dietConfluent plaquesRadiologic findingsFat necrosisTreatment courseTherapeutic coolingSubsequent hypercalcemiaHypercalcemiaInfantile hypercalcemiaCalcium levelsPg/
2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical And Experimental Rheumatology 2016, 35 Suppl 106: 106-113. PMID: 27908301.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideNT-proBNP levelsPg/mLSSc-PHNT-proBNPPulmonary hypertensionSSc patientsSystemic sclerosisNatriuretic peptideBaseline B-type natriuretic peptideMedian B-type natriuretic peptideSystemic sclerosis-associated pulmonary hypertensionMulticenter prospective cohortNT-proBNP groupNatriuretic peptide levelsRight ventricular dysfunctionPredictors of mortalityPulmonary arterial hypertensionPredictors of progressionAssessment of patientsBaseline creatinineSSc-PAHArterial hypertensionPAH patientsVentricular dysfunctionVitamin D Status After Cardiopulmonary Bypass in Children With Congenital Heart Disease
Zahr R, Faustino EV, Carpenter T, Kirshbom P, Hall EK, Fahey JT, Kandil SB. Vitamin D Status After Cardiopulmonary Bypass in Children With Congenital Heart Disease. Journal Of Intensive Care Medicine 2016, 32: 508-513. PMID: 27251108, DOI: 10.1177/0885066616652077.Peer-Reviewed Original ResearchConceptsCongenital heart diseasePg/mLCardiopulmonary bypassVitamin D binding proteinD binding proteinHeart diseaseAlbumin levelsTime pointsVitamin D deficiencyVitamin D statusProspective observational studyMean levelsFree fractionD deficiencyD statusDihydroxyvitamin DObservational studySurgeryBinding proteinBypassDiseaseMeasures analysisChildrenDeficiencyML
2015
Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23
Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 2565-2573. PMID: 25919461, PMCID: PMC4495171, DOI: 10.1210/jc.2015-1551.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugDrug Administration ScheduleFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGlomerular Filtration RateHumansImmunoglobulin GMaleMiddle AgedPhosphorusRecombinant ProteinsTreatment OutcomeYoung AdultConceptsTmP/GFRSerum PiNormal rangeOpen-label phase 1/2 studyElevated fibroblast growth factor 23Fibroblast growth factor 23Phase 1/2 studyDose-escalation studyGlomerular filtration ratePre-dose levelsGrowth factor 23Favorable safety profileMain outcome measuresProportion of subjectsAcademic medical centerPeak PiSerum inorganic phosphorusPg/mLUrinary calciumDose escalationFactor 23Monthly dosesSerum phosphorusDihydroxyvitamin DSafety profileConcentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure
Motiwala SR, Gaggin HK, Gandhi PU, Belcher A, Weiner RB, Baggish AL, Szymonifka J, Januzzi JL. Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure. Journal Of Cardiovascular Translational Research 2015, 8: 164-172. PMID: 25777344, DOI: 10.1007/s12265-015-9618-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersChi-Square DistributionChronic DiseaseDisease ProgressionFemaleHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardiumNatriuretic Peptide, BrainNecrosisOdds RatioPeptide FragmentsPhenotypePredictive Value of TestsPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesRisk FactorsSystoleTime FactorsTroponin IVentricular Dysfunction, LeftVentricular Function, LeftVentricular RemodelingConceptsLV systolic dysfunctionChronic heart failureHeart failureLV remodelingSerial measurementsHigh-risk clinical featuresLower CV event ratesCV event ratesDeleterious LV remodelingIndependent risk informationPoor cardiovascular outcomesPoor CV outcomesProgressive LV remodelingSensitive cardiac troponinMajority of patientsSignificant myocardial necrosisSensitive troponin assaysPg/mLCV outcomesHsTnI concentrationsCardiovascular eventsCardiovascular outcomesSystolic dysfunctionAdverse remodelingClinical features
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply